CLN5
protein-codingCLN5 intracellular trafficking protein
Gene summary
This gene is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely encode proteins involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function.[provided by RefSeq, Oct 2008]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~28.5 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009745
Submitter: Myriad Women's Health
Inheritance Pattern: AR
Disease ID:MONDO:0009745
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0009745
Submitter: Genomics England PanelApp
Inheritance Pattern: AR
Disease ID:MONDO:0016295
Submitter: ClinGen
Neuronal ceroid lipofuscinoses (NCLs) are progressive neurodegenerative diseases characterized by mental and motor deterioration, epilepsy, visual loss, ataxia, and a reduced life span. The unifying finding in NCL patients is the accumulation, in neurons and many other cell types, of autofluorescent storage material. There are 13 subtypes of NCLs that are categorized based on the particular gene that is mutated. CLN5 is associated with autosomal recessive NCL, with typical onset in preschool or early childhood, often described as variant late infantile NCL (vLINCL). CLN5 is an intracellular trafficking protein that is implicated in recruitment of the retromer complex to endosomes. It is translated into a preprotein with an N-terminal transmembrane domain that is cleaved to form the active soluble protein. The historic nomenclature differs from the current nomenclature used in ClinVar and some more recent publications by 147 nucleotides / 49 amino acids. CLN5 was first identified as a cause of NCL in 1998 in a study that identified a founder mutation (c.1026_1027AT AKA AKA c.1175_1176delAT) in individuals with vLINCL from 17 familes (Savukoski et al., 1998, PMID: 9662406). Since then, more than 50 variants have been reported, and more than half are protein truncating (Kousi et al., 2012, PMID: 21990111; https://www.ucl.ac.uk/ncl//mutation.shtml). Eight symptomatic probands from unrelated families with homozygous or compound heterozygous CLN5 variants reported by five studies were scored for genetic evidence (PMID: 9662406, 20157158, 19201763, 18684116, 21990111). Four probands had homozygous nonsense or frameshift variants in the last exon that are expected to cause protein truncation and in the absence of functional studies are not proven to be null so were given a modified score. The remaining probands were homozygous or compound heterozygous for two variants in trans that were proven/predicted to be null, and were given scores of 2. Functional studies were used to upgrade the points for two probands with frameshift variants in the last exon. No LOD scores could be calculated from these families because only a single affected individual was reported or detailed family information was not provided. Supporting experimental evidence includes protein interaction with CLN2 (12134079), non-human model organisms (dog: 27203721), and rescue in non-human model organisms by adeno associated virus-mediated gene transfer (mouse: 17637720; dog: 26560358). In summary, a score of 12 was given to genetic evidence, and 2.5 to experimental evidence, reaching 14.5 in total. The association between CLN5 and NCL has been replicated over time and is therefore considered definitive.
Inheritance Pattern: AR
Disease ID:MONDO:0003004
Submitter: LiferaOmics
Genetic evidence – Published: PMID: 33507209 — Cohort study identifying 7 affected individuals with autosomal recessive macular dystrophy carrying the same bi-allelic missense CLN5 variant NM_006493.2:c.415T>C; p.(Phe139Leu); macular dystrophy phenotype with mild/absent neurologic involvement reported in mid-adulthood; segregation shown for at least one family (figure: segregation analysis confirms recessive inheritance). Because the reported allele is non-pLoF (missense), case-level points were assigned using the AR “other variant” default of 0.1 per proband, total 0.7 points (7 probands × 0.1). Segregation = 0.5 (conservative; no LOD provided). Case-control = 0 Published genetic evidence total = 1.2 / 12 Genetic evidence – Our case: 1 proband: parents consanguineous; missense; AR inheritance; no additional genotyped affected relatives; no segregation or case-control data. Because the allele is non-pLoF (missense), case-level points were assigned using the AR “other variant” default = 0.1. Segregation = 0; case-control = 0. Our case contribution = 0.1 / 12 Experimental evidence – Published: PMID: 28487519 — Cln5-deficient mouse model demonstrating progressive retinal degeneration and visual dysfunction, supporting a role for CLN5 in retinal integrity (supportive in vivo model). Points = 2.0 (animal model). Experimental evidence total = 2.0 / 6 Overall score = 3.3
Inheritance Pattern: AR
Disease ID:MONDO:0009745
Submitter: Natera
Inheritance Pattern: AR
Disease ID:MONDO:0009745
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0009745
Submitter: G2P
Clinical Genomic Database (CGD)
Manifestation: Biochemical; Neurologic; Ophthalmologic
Intervention: General
Rationale: Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to CLN5 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_006493.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 169 | 1 | 172 | ||
| missense | 2 | 22 | 185 | 5 | 2 | 216 |
| nonsense | 14 | 30 | 2 | 46 | ||
| start loss | 1 | 2 | 3 | |||
| frameshift | 40 | 48 | 2 | 90 | ||
| splice donor/acceptor (+/-2bp) | 3 | 13 | 2 | 18 | ||
| Total | 59 | 114 | 195 | 174 | 3 | 545 |
Highest pathogenic variant AF is 0.00008488302
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_006484.2 | 4 | MANE Select | |
| Ensembl | ENSP00000366673.5 | 4 | MANE Select | |
| RefSeq | NP_001353553.1 | 4 | Standard | |
| Ensembl | ENSP00000482959.3 | 3 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Lysosome - Homo sapiens (human)
Biological Process
- signal peptide processing
- lysosomal lumen acidification
- brain development
- neurogenesis
- protein catabolic process
Molecular Function
- protein binding
- mannose binding
Cellular Component
- lysosome
- lysosomal membrane
- endoplasmic reticulum
- Golgi apparatus
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000377453
- Coding exons
- 4
- Length
- 11858
- Individuals with no LoFs
- 125699
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 49
- Defined
- 125748
- p
- 0.000195
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.123 | 226 | 221 | 1.02 | 0.0000103 | 2629 |
| Missense (PolyPhen) | 68 | 84.975 | 0.80023 | 1029 | ||
| Synonymous | 0.671 | 76 | 83.8 | 0.907 | 0.00000393 | 784 |
| Loss of Function | 0.846 | 14 | 17.9 | 0.784 | 9.09e-7 | 203 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000062 | 0.000062 | rare |
| Latino/Admixed American | 0.00044 | 0.00043 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00016 | 0.00016 | rare |
| Finnish | 0.000092 | 0.000092 | rare |
| European (Non-Finnish) | 0.00025 | 0.00024 | rare |
| South Asian | 0.000033 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Plays a role in influencing the retrograde trafficking of lysosomal sorting receptors SORT1 and IGF2R from the endosomes to the trans-Golgi network by controlling the recruitment of retromer complex to the endosomal membrane. Regulates the localization and activation of RAB7A which is required to recruit the retromer complex to the endosomal membrane (PubMed:22431521). {ECO:0000269|PubMed:22431521}.;
- Disease
- DISEASE: Ceroid lipofuscinosis, neuronal, 5 (CLN5) [MIM:256731]: A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 5 comprise mixed combinations of granular, curvilinear, and fingerprint profiles. {ECO:0000269|PubMed:15728307, ECO:0000269|PubMed:16814585, ECO:0000269|PubMed:17607606, ECO:0000269|PubMed:19309691, ECO:0000269|PubMed:20052765, ECO:0000269|PubMed:21990111, ECO:0000269|PubMed:24038957, ECO:0000269|PubMed:24058541, ECO:0000269|PubMed:26342652, ECO:0000269|PubMed:9662406}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.166
Intolerance Scores
- LoFtool
- 0.287
- RVIS EVS
- 0.06
- RVIS percentile EVS
- 58.74
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.386
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |